Pancreatic cancer (PaC) is one of the most lethal cancers, with an increasing global incidence rate. Unfavorable prognosis largely results from associated difficulties in early diagnosis and the absence of prognostic and predictive biomarkers that would enable an individualized therapeutic approach. In fact, PaC prognosis has not improved for years, even though much efforts and resources have been devoted to PaC research, and the multimodal management of PaC patients has been used in clinical practice. It is thus imperative to develop optimal biomarkers, which would increase diagnostic precision and improve the post-diagnostic management of PaC patients. Current trends in biomarker research envisage the unique opportunity of cell-free microRNAs (miRNAs) present in circulation to become a convenient, non-invasive tool for accurate diagnosis, prognosis and prediction of response to treatment. This review analyzes studies focused on cell-free miRNAs in PaC. The studies provide solid evidence that miRNAs are detectable in serum, blood plasma, saliva, urine, and stool, and that they present easy-to-acquire biomarkers with strong diagnostic, prognostic and predictive potential.

Central European Institute of Technology Masaryk University Brno Czech Republic; 2Department of Surgery Institutions shared with the Faculty Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic; 3Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic

Zobrazit více v PubMed

Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136(5):E359–E386. [http://dx.doi.org/10.1002/ijc.29210]. [PMID: 25220842]. PubMed

Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68(1):7–30. [http://dx.doi.org/10.3322/caac.21442]. [PMID: 29313949]. PubMed

Wong M.C.S., Jiang J.Y., Liang M., Fang Y., Yeung M.S., Sung J.J.Y. Global temporal patterns of pancreatic cancer and association with socioeconomic development. Sci. Rep. 2017;7(1):3165. [http://dx.doi.org/10.1038/s41598-017-02997-2]. [PMID: 28600530]. PubMed PMC

Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–620. [http://dx.doi.org/10.1016/S0140-6736(10)62307-0]. [PMID: 21620466]. PubMed PMC

Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., Reichert M., Beatty G.L., Rustgi A.K., Vonderheide R.H., Leach S.D., Stanger B.Z. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1-2):349–361. [http://dx.doi.org/10.1016/j.cell.2011.11.025]. [PMID: 22265420]. PubMed PMC

Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J., Büchler M.W. European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004;350(12):1200–1210. [http://dx.doi.org/10.1056/NEJMoa032295]. [PMID: 15028824]. PubMed

Neoptolemos J.P., Palmer D.H., Ghaneh P., Psarelli E.E., Valle J.W., Halloran C.M., Faluyi O., O’Reilly D.A., Cunningham D., Wadsley J., Darby S., Meyer T., Gillmore R., Anthoney A., Lind P., Glimelius B., Falk S., Izbicki J.R., Middleton G.W., Cummins S., Ross P.J., Wasan H., McDonald A., Crosby T., Ma Y.T., Patel K., Sherriff D., Soomal R., Borg D., Sothi S., Hammel P., Hackert T., Jackson R., Büchler M.W. European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–1024. [http://dx.doi.org/10.1016/S0140-6736(16)32409-6]. [PMID: 28129987]. PubMed

Neoptolemos J.P., Stocken D.D., Tudur Smith C., Bassi C., Ghaneh P., Owen E., Moore M., Padbury R., Doi R., Smith D., Büchler M.W. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br. J. Cancer. 2009;100(2):246–250. [http://dx.doi.org/10.1038/sj.bjc.6604838]. [PMID: 19127260]. PubMed PMC

Oettle H., Neuhaus P., Hochhaus A., Hartmann J.T., Gellert K., Ridwelski K., Niedergethmann M., Zülke C., Fahlke J., Arning M.B., Sinn M., Hinke A., Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–1481. [http://dx.doi.org/10.1001/jama.2013.279201]. [PMID: 24104372]. PubMed

Valle J.W., Palmer D., Jackson R., Cox T., Neoptolemos J.P., Ghaneh P., Rawcliffe C.L., Bassi C., Stocken D.D., Cunningham D., O’Reilly D., Goldstein D., Robinson B.A., Karapetis C., Scarfe A., Lacaine F., Sand J., Izbicki J.R., Mayerle J., Dervenis C., Oláh A., Butturini G., Lind P.A., Middleton M.R., Anthoney A., Sumpter K., Carter R., Büchler M.W. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J. Clin. Oncol. 2014;32(6):504–512. [http://dx.doi.org/10.1200/JCO.2013.50.7657]. [PMID: 24419109]. PubMed

American Cancer Society. Survival Rates for Pancreatic Cancer. https://www.cancer.org/cancer/pancreatic-cancer/ detection-diagnosis-staging/survival-rates.html Available from:

Schanen B.C., Li X. Transcriptional regulation of mammalian miRNA genes. Genomics. 2011;97(1):1–6. [http://dx.doi.org/10.1016/j.ygeno.2010.10.005]. [PMID: 20977933]. PubMed PMC

Galatenko V.V., Galatenko A.V., Samatov T.R., Turchinovich A.A., Shkurnikov M.Y., Makarova J.A., Tonevitsky A.G. Comprehensive network of miRNA-induced intergenic interactions and a biological role of its core in cancer. Sci. Rep. 2018;8(1):2418. [http://dx.doi.org/10.1038/s41598-018-20215-5]. [PMID: 29402894]. PubMed PMC

Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., Li Q., Li X., Wang W., Zhang Y., Wang J., Jiang X., Xiang Y., Xu C., Zheng P., Zhang J., Li R., Zhang H., Shang X., Gong T., Ning G., Wang J., Zen K., Zhang J., Zhang C.Y. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006. [http://dx.doi.org/10.1038/cr.2008.282]. [PMID: 18766170]. PubMed

Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O’Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA. 2008;105(30):10513–10518. [http://dx.doi.org/10.1073/pnas.0804549105]. [PMID: 18663219]. PubMed PMC

Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., Galas D.J., Wang K. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010;56(11):1733–1741. [http://dx.doi.org/10.1373/clinchem.2010.147405]. [PMID: 20847327]. PubMed PMC

Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008;110(1):13–21. [http://dx.doi.org/10.1016/j.ygyno.2008.04.033]. [PMID: 18589210]. PubMed

Su M.J., Aldawsari H., Amiji M. Pancreatic cancer cell exosome-mediated macrophage reprogramming and the role of microRNAs 155 and 125b2 transfection using nanoparticle delivery systems. Sci. Rep. 2016;6:30110. [http://dx.doi.org/10.1038/srep30110]. [PMID: 27443190]. PubMed PMC

Falcone G., Felsani A., D’Agnano I. Signaling by exosomal microRNAs in cancer. J. Exp. Clin. Cancer Res. 2015;34:32. [http://dx.doi.org/10.1186/s13046-015-0148-3]. [PMID: 25886763]. PubMed PMC

Turchinovich A., Weiz L., Langheinz A., Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223–7233. [http://dx.doi.org/10.1093/nar/gkr254]. [PMID: 21609964]. PubMed PMC

Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., Mitchell P.S., Bennett C.F., Pogosova-Agadjanyan E.L., Stirewalt D.L., Tait J.F., Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. USA. 2011;108(12):5003–5008. [http://dx.doi.org/10.1073/pnas.1019055108]. [PMID: 21383194]. PubMed PMC

Wang K., Zhang S., Weber J., Baxter D., Galas D.J. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010;38(20):7248–7259. [http://dx.doi.org/10.1093/nar/gkq601]. [PMID: 20615901]. PubMed PMC

Turchinovich A., Burwinkel B. Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol. 2012;9(8):1066–1075. [http://dx.doi.org/10.4161/rna.21083]. [PMID: 22858679]. PubMed PMC

Jiang L., Paone S., Caruso S., Atkin-Smith G.K., Phan T.K., Hulett M.D., Poon I.K.H. Determining the contents and cell origins of apoptotic bodies by flow cytometry. Sci. Rep. 2017;7(1):14444. [http://dx.doi.org/10.1038/s41598-017-14305-z]. [PMID: 29089562]. PubMed PMC

Zernecke A., Bidzhekov K., Noels H., Shagdarsuren E., Gan L., Denecke B., Hristov M., Köppel T., Jahantigh M.N., Lutgens E., Wang S., Olson E.N., Schober A., Weber C. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal. 2009;2(100):ra81. [http://dx.doi.org/10.1126/scisignal.2000610]. [PMID: 19996457]. PubMed

Tiberio P., Callari M., Angeloni V., Daidone M.G., Appierto V. Challenges in using circulating miRNAs as cancer biomarkers. BioMed Res. Int. 2015;•••:2015731479. [http://dx.doi.org/10.1155/2015/731479]. [PMID: 25874226]. PubMed PMC

Pritchard C.C., Kroh E., Wood B., Arroyo J.D., Dougherty K.J., Miyaji M.M., Tait J.F., Tewari M. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev. Res. (Phila.) 2012;5(3):492–497. [http://dx.doi.org/10.1158/1940-6207.CAPR-11-0370]. [PMID: 22158052]. PubMed PMC

Moret I., Sánchez-Izquierdo D., Iborra M., Tortosa L., Navarro-Puche A., Nos P., Cervera J., Beltrán B. Assessing an improved protocol for plasma microRNA extraction. PLoS One. 2013;8(12):e82753. [http://dx.doi.org/10.1371/journal.pone.0082753]. [PMID: 24376572]. PubMed PMC

Kroh E.M., Parkin R.K., Mitchell P.S., Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50(4):298–301. [http://dx.doi.org/10.1016/j.ymeth.2010.01.032]. [PMID: 20146939]. PubMed PMC

McAlexander M.A., Phillips M.J., Witwer K.W. Comparison of methods for miRNA extraction from plasma and quantitative recovery of RNA from cerebrospinal fluid. Front. Genet. 2013;4:83. [http://dx.doi.org/10.3389/fgene.2013.00083]. [PMID: 23720669]. PubMed PMC

Duy J., Koehler J.W., Honko A.N., Minogue T.D. Optimized microRNA purification from TRIzol-treated plasma. BMC Genomics. 2015;16:95. [http://dx.doi.org/10.1186/s12864-015-1299-5]. [PMID: 25765146]. PubMed PMC

Kopkova A., Sana J., Fadrus P., Slaby O. Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors. Clin. Chem. Lab. Med. 2018;56(6):869–879. [http://dx.doi.org/10.1515/cclm-2017-0958]. [PMID: 29451858]. PubMed

Garcia-Elias A., Alloza L., Puigdecanet E., Nonell L., Tajes M., Curado J., Enjuanes C., Díaz O., Bruguera J., Martí-Almor J., Comín-Colet J., Benito B. Defining quantification methods and optimizing protocols for microarray hybridization of circulating microRNAs. Sci. Rep. 2017;7(1):7725. [http://dx.doi.org/10.1038/s41598-017-08134-3]. [PMID: 28798363]. PubMed PMC

Zampetaki A., Mayr M. Analytical challenges and technical limitations in assessing circulating miRNAs. Thromb. Haemost. 2012;108(4):592–598. [PMID: 22627831]. PubMed

Poel D., Buffart T.E., Oosterling-Jansen J., Verheul H.M., Voortman J. Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. Exp. Mol. Med. 2018;50(3):e454. [http://dx.doi.org/10.1038/emm.2017.288]. [PMID: 29520111]. PubMed PMC

Pimentel F., Bonilla P., Ravishankar Y.G., Contag A., Gopal N., LaCour S., Lee T., Niemz A. Technology in microRNA profiling: circulating MicroRNAs as noninvasive cancer biomarkers in breast cancer. J. Lab. Autom. 2015;20(5):574–588. [http://dx.doi.org/10.1177/2211068214561788]. [PMID: 25524488]. PubMed

Mattie M.D., Benz C.C., Bowers J., Sensinger K., Wong L., Scott G.K., Fedele V., Ginzinger D., Getts R., Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer. 2006;5:24. [http://dx.doi.org/10.1186/1476-4598-5-24]. [PMID: 16784538]. PubMed PMC

Tan G.W., Khoo A.S., Tan L.P. Evaluation of extraction kits and RT-qPCR systems adapted to high-throughput platform for circulating miRNAs. Sci. Rep. 2015;5:9430. [http://dx.doi.org/10.1038/srep09430]. [PMID: 25800946]. PubMed PMC

Rubio M., Bustamante M., Hernandez-Ferrer C., Fernandez-Orth D., Pantano L., Sarria Y., Piqué-Borras M., Vellve K., Agramunt S., Carreras R., Estivill X., Gonzalez J.R., Mayor A. Circulating miRNAs, isomiRs and small RNA clusters in human plasma and breast milk. PLoS One. 2018;13(3):e0193527. [http://dx.doi.org/10.1371/journal.pone.0193527]. [PMID: 29505615]. PubMed PMC

Vorvis C., Koutsioumpa M., Iliopoulos D. Developments in miRNA gene signaling pathways in pancreatic cancer. Future Oncol. 2016;12(9):1135–1150. [http://dx.doi.org/10.2217/fon-2015-0050]. [PMID: 26984178]. PubMed PMC

Bryant K.L., Mancias J.D., Kimmelman A.C., Der C.J. KRAS: feeding pancreatic cancer proliferation. Trends Biochem. Sci. 2014;39(2):91–100. [http://dx.doi.org/10.1016/j.tibs.2013.12.004]. [PMID: 24388967]. PubMed PMC

Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–1806. [http://dx.doi.org/10.1126/science.1164368]. [PMID: 18772397]. PubMed PMC

di Magliano M.P., Logsdon C.D. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology. 2013;144(6):1220–1229. [http://dx.doi.org/10.1053/j.gastro.2013.01.071]. [PMID: 23622131]. PubMed PMC

Jonckheere N., Vasseur R., Van Seuningen I. The cornerstone K-RAS mutation in pancreatic adenocarcinoma: from cell signaling network, target genes, biological processes to therapeutic targeting. Crit. Rev. Oncol. Hematol. 2017;111:7–19. [http://dx.doi.org/10.1016/j.critrevonc.2017.01.002]. [PMID: 28259298]. PubMed

Zhao W.G., Yu S.N., Lu Z.H., Ma Y.H., Gu Y.M., Chen J. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis. 2010;31(10):1726–1733. [http://dx.doi.org/10.1093/carcin/bgq160]. [PMID: 20675343]. PubMed

Giovannetti E., Funel N., Peters G.J., Del Chiaro M., Erozenci L.A., Vasile E., Leon L.G., Pollina L.E., Groen A., Falcone A., Danesi R., Campani D., Verheul H.M., Boggi U. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010;70(11):4528–4538. [http://dx.doi.org/10.1158/0008-5472.CAN-09-4467]. [PMID: 20460539]. PubMed

Paik W.H., Kim H.R., Park J.K., Song B.J., Lee S.H., Hwang J.H. Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol. Anticancer Res. 2013;33(4):1473–1481. [PMID: 23564788]. PubMed

Wei X., Wang W., Wang L., Zhang Y., Zhang X., Chen M., Wang F., Yu J., Ma Y., Sun G. MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4. Cancer Med. 2016;5(4):693–702. [http://dx.doi.org/10.1002/cam4.626]. [PMID: 26864640]. PubMed PMC

Mikamori M., Yamada D., Eguchi H., Hasegawa S., Kishimoto T., Tomimaru Y., Asaoka T., Noda T., Wada H., Kawamoto K., Gotoh K., Takeda Y., Tanemura M., Mori M., Doki Y. MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma. Sci. Rep. 2017;7:42339. [http://dx.doi.org/10.1038/srep42339]. [PMID: 28198398]. PubMed PMC

Tang Y., Tang Y., Cheng Y.S. miR-34a inhibits pancreatic cancer progression through Snail1-mediated epithelial-mesenchymal transition and the Notch signaling pathway. Sci. Rep. 2017;7:38232. [http://dx.doi.org/10.1038/srep38232]. [PMID: 28145431]. PubMed PMC

Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., Xiang D., Desano J.T., Bommer G.T., Fan D., Fearon E.R., Lawrence T.S., Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4(8):e6816. [http://dx.doi.org/10.1371/journal.pone.0006816]. [PMID: 19714243]. PubMed PMC

Gu J., Wang D., Zhang J., Zhu Y., Li Y., Chen H., Shi M., Wang X., Shen B., Deng X., Zhan Q., Wei G., Peng C. GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. Cancer Lett. 2016;380(2):434–441. [http://dx.doi.org/10.1016/j.canlet.2016.06.016]. [PMID: 27400681]. PubMed

Tempero M.A., Malafa M.P., Al-Hawary M., Asbun H., Bain A., Behrman S.W., Benson A.B., III, Binder E., Cardin D.B., Cha C., Chiorean E.G., Chung V., Czito B., Dillhoff M., Dotan E., Ferrone C.R., Hardacre J., Hawkins W.G., Herman J., Ko A.H., Komanduri S., Koong A., LoConte N., Lowy A.M., Moravek C., Nakakura E.K., O’Reilly E.M., Obando J., Reddy S., Scaife C., Thayer S., Weekes C.D., Wolff R.A., Wolpin B.M., Burns J., Darlow S. Pancreatic adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2017;15(8):1028–1061. [http://dx.doi.org/10.6004/jnccn.2017.0131]. [PMID: 28784865]. PubMed

Ballehaninna U.K., Chamberlain R.S. Serum CA 19-9 as a biomarker for pancreatic cancer-a comprehensive review. Indian J. Surg. Oncol. 2011;2(2):88–100. [http://dx.doi.org/10.1007/s13193-011-0042-1]. [PMID: 22693400]. PubMed PMC

Wang J., Chen J., Chang P., LeBlanc A., Li D., Abbruzzesse J.L., Frazier M.L., Killary A.M., Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. (Phila.) 2009;2(9):807–813. [http://dx.doi.org/10.1158/1940-6207.CAPR-09-0094]. [PMID: 19723895]. PubMed PMC

Ho A.S., Huang X., Cao H., Christman-Skieller C., Bennewith K., Le Q.T., Koong A.C. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl. Oncol. 2010;3(2):109–113. [http://dx.doi.org/10.1593/tlo.09256]. [PMID: 20360935]. PubMed PMC

Morimura R., Komatsu S., Ichikawa D., Takeshita H., Tsujiura M., Nagata H., Konishi H., Shiozaki A., Ikoma H., Okamoto K., Ochiai T., Taniguchi H., Otsuji E. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br. J. Cancer. 2011;105(11):1733–1740. [http://dx.doi.org/10.1038/bjc.2011.453]. [PMID: 22045190]. PubMed PMC

Cote G.A., Gore A.J., McElyea S.D., Heathers L.E., Xu H., Sherman S., Korc M. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile. Am. J. Gastroenterol. 2014;109(12):1942–1952. [http://dx.doi.org/10.1038/ajg.2014.331]. [PMID: 25350767]. PubMed PMC

Alemar B., Izetti P., Gregório C., Macedo G.S., Castro M.A., Osvaldt A.B., Matte U., Ashton-Prolla P. miRNA-21 and miRNA-34a are potential minimally invasive biomarkers for the diagnosis of pancreatic ductal adenocarcinoma. Pancreas. 2016;45(1):84–92. [http://dx.doi.org/10.1097/MPA.0000000000000383]. [PMID: 26262588]. PubMed

Deng T., Yuan Y., Zhang C., Zhang C., Yao W., Wang C., Liu R., Ba Y. Identification of circulating MiR-25 as a potential biomarker for pancreatic cancer diagnosis. Cell. Physiol. Biochem. 2016;39(5):1716–1722. [http://dx.doi.org/10.1159/000447872]. [PMID: 27639768]. PubMed

Ganepola G.A., Rutledge J.R., Suman P., Yiengpruksawan A., Chang D.H. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J. Gastrointest. Oncol. 2014;6(1):22–33. [http://dx.doi.org/10.4251/wjgo.v6.i1.22]. [PMID: 24578785]. PubMed PMC

Abue M., Yokoyama M., Shibuya R., Tamai K., Yamaguchi K., Sato I., Tanaka N., Hamada S., Shimosegawa T., Sugamura K., Satoh K. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int. J. Oncol. 2015;46(2):539–547. [http://dx.doi.org/10.3892/ijo.2014.2743]. [PMID: 25384963]. PubMed PMC

Permuth-Wey J., Chen D.T., Fulp W.J., Yoder S.J., Zhang Y., Georgeades C., Husain K., Centeno B.A., Magliocco A.M., Coppola D., Malafa M. Plasma microRNAs as novel biomarkers for patients with intraductal papillary mucinous neoplasms of the pancreas. Cancer Prev. Res. (Phila.) 2015;8(9):826–834. [http://dx.doi.org/10.1158/1940-6207.CAPR-15-0094]. [PMID: 26314797]. PubMed PMC

Goto T., Fujiya M., Konishi H., Sasajima J., Fujibayashi S., Hayashi A., Utsumi T., Sato H., Iwama T., Ijiri M., Sakatani A., Tanaka K., Nomura Y., Ueno N., Kashima S., Moriichi K., Mizukami Y., Kohgo Y., Okumura T. An elevated expression of serum exosomal microRNA-191, - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker. BMC Cancer. 2018;18(1):116. [http://dx.doi.org/10.1186/s12885-018-4006-5]. [PMID: 29385987]. PubMed PMC

Duell E.J., Lujan-Barroso L., Sala N., Deitz McElyea S., Overvad K., Tjonneland A., Olsen A., Weiderpass E., Busund L.T., Moi L., Muller D., Vineis P., Aune D., Matullo G., Naccarati A., Panico S., Tagliabue G., Tumino R., Palli D., Kaaks R., Katzke V.A., Boeing H., Bueno-de-Mesquita H.B.A., Peeters P.H., Trichopoulou A., Lagiou P., Kotanidou A., Travis R.C., Wareham N., Khaw K.T., Ramon Quiros J., Rodríguez-Barranco M., Dorronsoro M., Chirlaque M.D., Ardanaz E., Severi G., Boutron-Ruault M.C., Rebours V., Brennan P., Gunter M., Scelo G., Cote G., Sherman S., Korc M. Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. Int. J. Cancer. 2017;141(5):905–915. [http://dx.doi.org/10.1002/ijc.30790]. [PMID: 28542740]. PubMed PMC

Franklin O., Jonsson P., Billing O., Lundberg E., Öhlund D., Nyström H., Lundin C., Antti H., Sund M. Plasma micro-RNA alterations appear late in pancreatic cancer. Ann. Surg. 2018;267(4):775–781. [http://dx.doi.org/10.1097/SLA.0000000000002124]. [PMID: 28425921]. PubMed PMC

Li A., Yu J., Kim H., Wolfgang C.L., Canto M.I., Hruban R.H., Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin. Cancer Res. 2013;19(13):3600–3610. [http://dx.doi.org/10.1158/1078-0432.CCR-12-3092]. [PMID: 23697990]. PubMed PMC

Liu R., Chen X., Du Y., Yao W., Shen L., Wang C., Hu Z., Zhuang R., Ning G., Zhang C., Yuan Y., Li Z., Zen K., Ba Y., Zhang C.Y. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin. Chem. 2012;58(3):610–618. [http://dx.doi.org/10.1373/clinchem.2011.172767]. [PMID: 22194634]. PubMed

Xu J., Cao Z., Liu W., You L., Zhou L., Wang C., Lou W., Sun B., Miao Y., Liu X., Zhang T., Zhao Y. Plasma miRNAs effectively distinguish patients with pancreatic cancer from controls: a multicenter study. Ann. Surg. 2016;263(6):1173–1179. [http://dx.doi.org/10.1097/SLA.0000000000001345]. [PMID: 26114496]. PubMed

Cao Z., Liu C., Xu J., You L., Wang C., Lou W., Sun B., Miao Y., Liu X., Wang X., Zhang T., Zhao Y. Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. Oncotarget. 2016;7(27):41575–41583. [http://dx.doi.org/10.18632/oncotarget.9491]. [PMID: 27223429]. PubMed PMC

Xie Z., Yin X., Gong B., Nie W., Wu B., Zhang X., Huang J., Zhang P., Zhou Z., Li Z. Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer. Cancer Prev. Res. (Phila.) 2015;8(2):165–173. [http://dx.doi.org/10.1158/1940-6207.CAPR-14-0192]. [PMID: 25538087]. PubMed

Humeau M., Vignolle-Vidoni A., Sicard F., Martins F., Bournet B., Buscail L., Torrisani J., Cordelier P. Salivary microRNA in pancreatic cancer patients. PLoS One. 2015;10(6):e0130996. [http://dx.doi.org/10.1371/journal.pone.0130996]. [PMID: 26121640]. PubMed PMC

Tanase C.P., Neagu M., Albulescu R., Hinescu M.E. Advances in pancreatic cancer detection. Adv. Clin. Chem. 2010;51:145–180. [http://dx.doi.org/10.1016/S0065-2423(10)51006-0]. [PMID: 20857621]. PubMed

Ren Y., Gao J., Liu J.Q., Wang X.W., Gu J.J., Huang H.J., Gong Y.F., Li Z.S. Differential signature of fecal microRNAs in patients with pancreatic cancer. Mol. Med. Rep. 2012;6(1):201–209. [PMID: 22504911]. PubMed

Yang J.Y., Sun Y.W., Liu D.J., Zhang J.F., Li J., Hua R. MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. Am. J. Cancer Res. 2014;4(6):663–673. [PMID: 25520858]. PubMed PMC

Link A., Becker V., Goel A., Wex T., Malfertheiner P. Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. PLoS One. 2012;7(8):e42933. [http://dx.doi.org/10.1371/journal.pone.0042933]. [PMID: 22905187]. PubMed PMC

Juracek J., Peltanova B., Dolezel J., Fedorko M., Pacik D., Radova L., Vesela P., Svoboda M., Slaby O., Stanik M. Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer. J. Cell. Mol. Med. 2018;22(3):2033–2038. [http://dx.doi.org/10.1111/jcmm.13487]. [PMID: 29363887]. PubMed PMC

Braicu C., Cojocneanu-Petric R., Chira S., Truta A., Floares A., Petrut B., Achimas-Cadariu P., Berindan-Neagoe I. Clinical and pathological implications of miRNA in bladder cancer. Int. J. Nanomedicine. 2015;10:791–800. [http://dx.doi.org/10.2147/IJN.S72904]. [PMID: 25653521]. PubMed PMC

Debernardi S., Massat N.J., Radon T.P., Sangaralingam A., Banissi A., Ennis D.P., Dowe T., Chelala C., Pereira S.P., Kocher H.M., Young B.D., Bond-Smith G., Hutchins R., Crnogorac-Jurcevic T. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. Am. J. Cancer Res. 2015;5(11):3455–3466. [PMID: 26807325]. PubMed PMC

Kong X., Du Y., Wang G., Gao J., Gong Y., Li L., Zhang Z., Zhu J., Jing Q., Qin Y., Li Z. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig. Dis. Sci. 2011;56(2):602–609. [http://dx.doi.org/10.1007/s10620-010-1285-3]. [PMID: 20614181]. PubMed

Yu Q., Xu C., Yuan W., Wang C., Zhao P., Chen L., Ma J. Evaluation of plasma microRNAs as diagnostic and prognostic biomarkers in pancreatic adenocarcinoma: miR-196a and miR-210 could be negative and positive prognostic markers, respectively. BioMed Res. Int. 2017;2017:6495867. [http://dx.doi.org/10.1155/2017/6495867]. [PMID: 28466015]. PubMed PMC

Kawaguchi T., Komatsu S., Ichikawa D., Morimura R., Tsujiura M., Konishi H., Takeshita H., Nagata H., Arita T., Hirajima S., Shiozaki A., Ikoma H., Okamoto K., Ochiai T., Taniguchi H., Otsuji E. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br. J. Cancer. 2013;108(2):361–369. [http://dx.doi.org/10.1038/bjc.2012.546]. [PMID: 23329235]. PubMed PMC

Sun B., Liu X., Gao Y., Li L., Dong Z. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients. Br. J. Biomed. Sci. 2016;73(4):152–157. [http://dx.doi.org/10.1080/09674845.2016.1220706]. [PMID: 27922430]. PubMed

Chen Q., Yang L., Xiao Y., Zhu J., Li Z. Circulating microRNA-182 in plasma and its potential diagnostic and prognostic value for pancreatic cancer. Med. Oncol. 2014;31(11):225. [http://dx.doi.org/10.1007/s12032-014-0225-z]. [PMID: 25326859]. PubMed

Miyamae M., Komatsu S., Ichikawa D., Kawaguchi T., Hirajima S., Okajima W., Ohashi T., Imamura T., Konishi H., Shiozaki A., Morimura R., Ikoma H., Ochiai T., Okamoto K., Taniguchi H., Otsuji E. Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer. Br. J. Cancer. 2015;113(10):1467–1476. [http://dx.doi.org/10.1038/bjc.2015.366]. [PMID: 26505678]. PubMed PMC

Imamura T., Komatsu S., Ichikawa D., Miyamae M., Okajima W., Ohashi T., Kiuchi J., Nishibeppu K., Konishi H., Shiozaki A., Morimura R., Ikoma H., Ochiai T., Okamoto K., Taniguchi H., Otsuji E. Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer. Sci. Rep. 2017;7(1):5708. [http://dx.doi.org/10.1038/s41598-017-06137-8]. [PMID: 28720759]. PubMed PMC

Hua Y., Chen H., Wang L., Wang F., Wang P., Ning Z., Li Y., Liu L., Chen Z., Meng Z. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer. Cancer Biomark. 2017;20(1):95–100. [http://dx.doi.org/10.3233/CBM-170231]. [PMID: 28759959]. PubMed

Takahasi K., Iinuma H., Wada K., Minezaki S., Kawamura S., Kainuma M., Ikeda Y., Shibuya M., Miura F., Sano K. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma. J. Hepatobiliary Pancreat. Sci. 2018;25(2):155–161. [http://dx.doi.org/10.1002/jhbp.524]. [PMID: 29130611]. PubMed

Negoi I., Hostiuc S., Sartelli M., Negoi R.I., Beuran M. MicroRNA-21 as a prognostic biomarker in patients with pancreatic cancer - A systematic review and meta-analysis. Am. J. Surg. 2017;214(3):515–524. [http://dx.doi.org/10.1016/j.amjsurg.2017.03.049]. [PMID: 28477839]. PubMed

Wang P., Zhuang L., Zhang J., Fan J., Luo J., Chen H., Wang K., Liu L., Chen Z., Meng Z. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol. Oncol. 2013;7(3):334–345. [http://dx.doi.org/10.1016/j.molonc.2012.10.011]. [PMID: 23177026]. PubMed PMC

Karasek P., Gablo N., Hlavsa J., Kiss I., Vychytilova-Faltejskova P., Hermanova M., Kala Z., Slaby O., Prochazka V. Pre-operative plasma miR-21-5p is a sensitive biomarker and independent prognostic factor in patients with pancreatic ductal adenocarcinoma undergoing surgical resection. Cancer Genomics Proteomics. 2018;15(4):321–327. [http://dx.doi.org/10.21873/cgp.20090]. [PMID: 29976637]. PubMed PMC

Que R., Ding G., Chen J., Cao L. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World J. Surg. Oncol. 2013;11:219. [http://dx.doi.org/10.1186/1477-7819-11-219]. [PMID: 24007214]. PubMed PMC